Recommendation of the President – Livtencity (maribavir)

On 10 September 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 94/2024 on the evaluation of Livtencity (maribavir) under the drug program “Treatment of patients with unresponsive or refractory cytomegalovirus (CMV) infection (ICD-10: B25.0, B25.1, B25.8, B25.9)”

Publication in Public Information Bulletin (BIP) >>